Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 11/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13089619 | 0.80 | NR3C2 (0.45) | NR3C2MMP12NR3C1PARP1CYP11B1 | |
| SCHEMBL20754037 | 0.77 | NR3C2 (0.43) | NR3C2MMP12NR3C1PARP1 | |
| SCHEMBL1333452 | 0.76 | NR3C2 (0.42) | NR3C2MMP12NR3C1CYP11B1CYP11B2 | |
| SCHEMBL1332897 | 0.76 | NR3C2 (0.42) | NR3C2MMP12NR3C1PARP1CYP11B1 | |
| SCHEMBL19629973 | 0.76 | NR3C2 (0.42) | NR3C2MMP12NR3C1PARP1KMT2A | |
| SCHEMBL13425021 | 0.76 | NR3C2 (0.45) | NR3C2MMP12NR3C1PARP1KCNH2 | |
| SCHEMBL1378747 | 0.74 | NR3C2 (0.41) | NR3C2MMP12NR3C1PARP1CYP11B1 | |
| SCHEMBL18425096 | 0.73 | MB (0.36) | MEN1KMT2ACYP11B1CYP11B2 | |
| SCHEMBL19430275 | 0.73 | MMP12 (0.39) | NR3C2MMP12PARP1MEN1KMT2A | |
| SCHEMBL2489889 | 0.71 | NR3C2 (0.50) | NR3C2MMP12NR3C1PARP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10711011-B2 | Substituted oxazolidines as anti-bacterial agents | Bugworks Research, Inc. (US) | 2020-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10711011-B2 | Substituted oxazolidines as anti-bacterial agents | ALPI, HLA-A, HLA-B | NR3C2 2377/4885MMP12 624/4885NR3C1 3666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.